Affordable Access

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

Authors
Publisher
Dove Press
Publication Date
Source
Legacy
Keywords
  • Drug Design
  • Development And Therapy
Disciplines
  • Medicine
  • Pharmacology

Abstract

Lilliana Oliveira, Russell D CohenThe Department of Medicine, Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL, USAAbstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission. Extended-release mesalamine is the first once daily mesalamine product approved by the Food and Drug Administration for the maintenance of UC remission. This review will examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, and discuss the potential role of improving medication compliance and decreasing costs in UC maintenance.Keywords: ulcerative colitis, 5-ASA, mesalamine, adherence, compliance, quality of life, costs

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments